Israel

Kitov Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Kitov Announces Initiation of Phase 1/2 Clinical Trial of NT219 in Advanced Cancer Patients

Lead Product(s): NT219,Cetuximab

Therapeutic Area: Oncology Product Name: NT219

Highest Development Status: Phase I/ Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 09, 2020

Details:

Company Evaluating NT219 as Monotherapy Treatment of Advanced Solid Tumors and in Combination with Cetuximab for the Treatment of Recurrent and/or Metastatic Solid Tumors and Head and Neck Cancer.

Compugen

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Compugen Gets FDA Clearance of IND Application for Phase 1/2 Triple Combination Study of COM701 with Opdivo and TIGIT Inhibitor

Lead Product(s): COM701,Nivolumab,BMS-986207

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 01, 2020

Details:

Study to evaluate simultaneous blockade of PVRIG, TIGIT and PD-1 immune checkpoints. te clinical evaluation of Compugen’s DNAM axis hypothesis and biomarker-driven approach in advanced solid tumors to broaden patient population responsive to cancer immunotherapy.

Kitov Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Kitov Pharma Expands Planned NT-219 Clinical Program for Difficult to Treat Cancers

Lead Product(s): NT-219,Cetuximab

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 24, 2020

Details:

Phase 1/2 study to evaluate NT-219 as Monotherapy Treatment of advanced solid tumors, as well as in combination with cetuximab to treat recurrent or metastatic Solid Tumors and Head and Neck Cancer.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Kitov Pharma

Kitov Announces Initiation of Phase 1/2 Clinical Trial of NT219 in Advanced Cancer Patients

Compugen

Compugen Gets FDA Clearance of IND Application for Phase 1/2 Triple Combination Study of COM701 with Opdivo and TIGIT Inhibitor

Kitov Pharma

Kitov Pharma Expands Planned NT-219 Clinical Program for Difficult to Treat Cancers